The effectiveness of autologous platelet concentrates in prevention and treatment of medication-related osteonecrosis of the jaws: A systematic review
Sylwia Maria Nowak B,Roberto Sacco,Fraser Mitchell,Vinod Patel,Katarzyna Gurzawska-Comis
DOI: https://doi.org/10.1016/j.jcms.2024.01.007
IF: 3.192
2024-02-02
Journal of Cranio-Maxillofacial Surgery
Abstract:Medication-related osteonecrosis of the jaw (MRONJ) is a disease caused by adverse effects of antiresorptive drugs (ARDs) and antiangiogenic drugs (AADs) commonly used in the treatment of cancer and osteoporosis. More recently, adjunctive drugs used for autoimmune and inflammatory conditions were reported to be linked with development of MRONJ (King et al., 2019). The risk of MRONJ is significantly higher in oncology patients than in osteoporotic patients, ranging from 0 % to 12 % (Khan et al., 2015; Lee et al., 2014; UK Chemotherapy Board, 2019) and 0.1 % respectively (Lo et al., 2010). Longer duration of intake, higher doses, intravenous route of administration and concurrent immunosuppressive medication increase this risk further. A thorough medical and drug history are critical to ascertain the patient's risk, and can aid planning to prevent the disease. Both national and international guidelines recommend dental assessment and treatment prior to the initiation of ARDs and AADs therapy (Beth-Tasdogan et al., 2022; Ruggiero et al., 2014, 2022). Educating patients about maintaining meticulous oral hygiene is also recommended in accordance with the Scottish Dental Clinical Effectiveness Program (SDCEP) Guidelines (2017) and the UK Chemotherapy Board (2019). There is increasing evidence that bacterial infection and inflammation may be an important factor in development of MRONJ (Otto et al., 2020; Ruggiero et al., 2022). In cases of established MRONJ, the current management can be categorised as conservative, surgical and adjuvant therapies. The literature is deficient of a standardised, definitive and systematic protocol for selection of the above treatment options. Increasing evidence advocates that surgical management of MRONJ may be more beneficial and successful compared to conservative non-surgical management (Aljohani et al., 2019; Hauer et al., 2020; Yamada et al., 2019). The American Association of Oral and Maxillofacial Surgeons (AAMOS) Position Paper (Ruggiero et al., 2014) was widely criticised for symptom-based management and reserving surgery for severe cases only. The updated Position Paper (Ruggiero et al., 2022) still offers staged-dictated protocols for both conservative and surgical management; however, in line with the emerging evidence, the guidance extended operative protocols for clinically appropriate Stages I, II and III. To be successful, the resection requires the margins to extend beyond the necrotic bone clearing an area of vital, bleeding bone. The margins of necrotic bone should be carefully defined using cone-beam computed tomography (CBCT), as there is some evidence to suggest that pre-surgical planning leads to long-term symptom resolution and complete mucosal closure (Aljohani et al., 2018; Yamada et al., 2019). Non-operative management includes local wound care, antimicrobial rinses and debridement of loose sequestera for all stages of the disease. Systemic antibiotic therapy is reserved for Stages II and III. Furthermore, adjuvant strategies for prevention and treatment of MRONJ have been proposed, including drug holiday (Damm & Jones, 2013), low-intensity laser therapy (LLT) (Latifyan et al., 2016; Weber et al., 2016) and application of autologous platelet concentrates (APCs) (de Souza Tolentino et al., 2019; Ruggiero et al., 2014). Recently APCs were investigated intensively due to their soft tissue regenerative properties, which may support mucosa healing, playing a crucial role in the success of MRONJ prevention and management. The high concentrations of growth factors in the APCs, including platelet-derived growth factors (PDGF), transforming growth factor β1 (TGF-β1), vascular endothelial growth factor (VEGF), and insulin growth factor-1 (IGF-I) lead to soft tissue healing, stimulation of angiogenesis and bone metabolism (Naik et al., 2013; O'Sullivan & NíRíordáin, 2022; Rusilas et al., 2020). The APCs can be delivered in different formation and are classified based on their fibrin architecture and leukocyte content (Dohan Ehrenfest et al., 2009). First-generation APCs are liquid platelet suspensions including pure platelet rich plasma (P-PRP), plasma rich in growth factors (PRGF), and leukocyte and platelet rich plasma (L-PRP). First-generation APCs require the addition of an anticoagulant which promotes gelification, that improves the handling properties and enables easier application of the PRP to the surgical site (O'Sullivan & NíRíordáin, 2022). Second generation APCs, pure platelet-rich fibrin (P-PRF) and leukocyte- and platelet-rich fibrin (L-PRF), form solid fibrin architecture without the need for anticoagulation. The pathophysiology of MRONJ is generally poorly understood. The main theories propose mechanisms of altered and/or suppressed bone remodelling, inhibition of angiogenesis, suppression of innate or acquired immunity, soft tissue toxicity and increased infection susceptibility (He et al -Abstract Truncated-
dentistry, oral surgery & medicine,surgery